EASL Journal Club
Now on demand!
Molecular-based targeted therapies in patients with hepatocellular carcinoma and hepato-cholangiocarcinoma refractory to atezolizumab/bevacizumab
EASL Studio
Wednesday 1 May, 18:00 CET
Assessment of clinically significant portal hypertension in 2024 – Is it time to say goodbye to invasive measurements?
EASL Quiz
Time for the new EASL Quiz
Test your Guidelines Knowledge!
EASL Molecular Tumour Board
On demand!
Catch up with the presentation and discussion of this clinical case of cholangiocarcinoma.
Steatotic liver disease – the missing piece in the NCD puzzle
Now on-demand!
Discover the priorities and recommendations for the upcoming WHA77 agenda established by EASL, representatives from the WHO, patient advocate, NCD Alliance, and more !
You may also be interested in
Our Sponsors